M&A Deal Summary

Triginta Capital Acquires Neurotech Pharmaceuticals

On September 3, 2008, private equity firm Triginta Capital acquired media company Neurotech Pharmaceuticals

Acquisition Highlights
  • This is Triginta Capital’s 1st transaction in the Media sector.
  • This is Triginta Capital’s 1st transaction in the United States.
  • This is Triginta Capital’s 1st transaction in Rhode Island.

M&A Deal Summary

Date 2008-09-03
Target Neurotech Pharmaceuticals
Sector Media
Buyer(s) Triginta Capital
Deal Type Buyout (LBO, MBO, MBI)

Target

Neurotech Pharmaceuticals

Lincoln, Rhode Island, United States
website
Developer of protein-drug delivery systems for the treatment of ophthalmologic diseases such as retinal degeneration (age-related macular degeneration, retinitis pigmentosa) and vascular eye diseases (diabetic retinopathy).

Search 193,240 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer
DESCRIPTION

Triginta Capital is a private equity firm focused on making control investments in small and medium-sized companies in German speaking Europe. Triginta generally seeks businesses valued up to €20 million in the manufacturing and services sectors (B2B and B2C). In addition to investing in companies, Triginta also acquires entire portfolios of investments. Triginta Capital was formed in 2000 and is based in Dusseldorf.


DEAL STATS #
Overall 11 of 11
Sector (Media) 1 of 1
Type (Buyout (LBO, MBO, MBI)) 8 of 8
State (Rhode Island) 1 of 1
Country (United States) 1 of 1
Year (2008) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-01-01 Chiracon

Luckenwalde, Germany

Development, production and distribution of chiral intermediates.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-02-26 COR pumps + compressors AG

Stuttgart, Germany

COR pumps + compressors AG (HTB) innovative technology to develop pumps and compressors.

Sell -